Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 25 of 175 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/13/18
End: 09/30/18
Due: 09/30/19
Phase: N/A
Priority: Normal
Start: 05/01/19
End: 05/01/22
Due: 05/01/23
Phase: N/A
Priority: Normal
Start: 06/01/24
End: 06/01/25
Due: 06/01/26
Phase: N/A
Priority: Normal
Start: 07/28/23
End: 06/30/24
Due: 06/30/25
Phase: N/A
Priority: Normal
Start: 04/01/22
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 02/01/24
End: 03/31/24
Due: 03/31/25
Phase: N/A
Priority: Normal
Start: 01/01/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 09/01/22
End: 09/01/30
Due: 09/01/31
Phase: N/A
Priority: Normal
Start: 09/30/13
End: 07/31/14
Due: 07/31/15
Phase: N/A
Priority: Normal
Start: 09/30/21
End: 06/30/22
Due: 06/30/23
Phase: N/A
Priority: Normal
Start: 12/26/24
End: 12/30/26
Due: 12/30/27
Phase: N/A
Priority: Normal
Start: 10/31/16
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 02/23/22
End: 06/30/23
Due: 06/30/24
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Phase: N/A
Priority: Normal
Start: 05/01/23
End: 12/30/24
Due: 12/30/25
Phase: N/A
Priority: Normal
Start: 06/22/21
End: 12/30/26
Due: 12/30/27
Phase: N/A
Priority: Normal
Start: 03/31/17
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 09/30/24
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 04/30/14
End: 04/30/15
Due: 04/30/16
Phase: N/A
Priority: Normal
Start: 08/26/24
End: 09/01/26
Due: 09/01/27
Phase: N/A
Priority: Normal
Start: 07/10/18
End: 03/01/19
Due: 03/01/20
Phase: N/A
Priority: Normal
Start: 01/18/16
End: 03/31/25
Due: 03/31/26
Phase: N/A
Priority: Normal
Start: 12/31/15
End: 09/30/17
Due: 09/30/18
Phase: N/A
Priority: Normal
Start: 10/01/18
End: 12/20/19
Due: 12/20/20
Phase: N/A
Priority: Normal
Start: 01/07/22
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 05/30/25
End: 12/31/25
Due: 12/31/26